Scholars Central

Conference abstractPublished 27 Jun 2016

The role of topoisomerase [IIA] as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer

Authors: A Barakat, F Zakaria, M Alm, M Gamea

University of Tanta, Egypt University Hospital Tanta, Egypt Gharbia Cancer Society, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Surrogate markers may be used to assess the response to neoadjuvant chemotherapy. The purpose of the study was to evaluate topoisomerase IIÃ?± as predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer patients. Tumor grade scored according to the Elston-Ellis classification, hormonal receptor (HR) status, tumor cell proliferation evaluated by Ki-67 staining, HER-2 and topoisomerase II alpha (TopoIIa) expression evaluated by immunohistochemistry (IHC). Method: Between January 2012 and June 2012, 50 locally advanced breast cancer patients had received 3 cycles neoadjuvant chemotherapy were studied in clinical oncology department at Tanta university. Regimens including either CEF (cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2, 5-fluorouracil 500 mg/m2) or FAC (cyclophosphamide 500 mg/m2, doxorubicin 50 mg/m2, 5 fluorouracil 500 mg/m2). Protein expression of HER2 and Topo IIÃ?± were determined by immunohistochemistry. The primary endpoint was pathological and clinical tumor response that assessed clinically and by mamography, then by pathological assessment. Results: Of 50 primary locally advanced breast cancer patients had been assessed after 3 cycles of NACT, the clinical complete response was in 6% (3/50), clinical partial response was in 86% (43/50) and overall clinical response was 92% (46/50), 4 (8%) patients had clinical stable disease and no one developed disease progression. 1-Responders had the following biomarkers criteria: Clinical (CR): 3 patients had co-expression of topo II and HER2, hormonal receptor negative and high KI-67. Clinical (PR): 43 patients majority of them had topo IIA over expression. 2-Non responders had the following criteria: 4 (8%) patients all had negative (TOPOII/HER2), low KI-67 and 2 had hormonal receptor positive and another 2 had hormonal receptor negative. Conclusion: Our study suggests that HER2 and Topo IIÃ?± overexpression could be predictors of the response to neoadjuvant chemotherapy in both the CEF and FAC arms.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “A Barakat”
  • BylineArticles whose byline prints “F Zakaria”
  • BylineArticles whose byline prints “M Alm”
  • BylineArticles whose byline prints “M Gamea”